A Phase II, Placebo-Controlled, Double-blind, Dose-Ranging (35 mg/day or 70 mg/day), Randomized, Multi-Centered Study of Cutaneo

Published: March 15th, 2012

Category: Projects

PI: Andresen, Elena, PhD
PI: Thomas Mulligan, MD; Dr. Unyime Nseyo, MD; April Tilton, PA-C
Funding Agency: Ascend Therapeutics, Inc and Pharmanet Inc.
Agency Project Number: 03-DHT-01/ IRB # 443-05
Study Goals:

The major goals of this project are to assess the affects of 35 mg/day and 70 mg/day DHT on body composition, libido and physical and sexual function in hypogonadal older men.

Key Personnel:

PI: Thomas Mulligan, MD Dr. Unyime Nseyo MD April Tilton, PA-C